Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

ClinicalTrials.gov ID: NCT00823979

Public ClinicalTrials.gov record NCT00823979. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b Multicenter, Randomized, Comparative Trial Of Uk-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleotide/Nucleoside Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced Hiv-1 Infected Subjects With Evidence Of Nnrti Resistant Hiv-1

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a 96 week study to determine if UK- 453,061 in combination with Darunavir /ritonavir and a Nucleos(t)ide Reverse Transcriptase inhibitor is as efficacious, safe and tolerable as etravirine in combination with Darunavir /ritonavir and a Nucleos(t)ide Reverse Transcriptase inhibitor in HIV-1 infected patients who have been previously treated with antiretroviral drugs and have NNRTI resistance mutations.

Study identification

NCT ID
NCT00823979
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
105 participants

Conditions and interventions

Conditions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 24, 2009
Primary completion
Oct 17, 2012
Completion
Oct 17, 2012
Last update posted
Dec 3, 2018

2009 – 2012

United States locations

U.S. sites
21
U.S. states
8
U.S. cities
17
Facility City State ZIP Site status
Jeffrey Goodman Special Care Clinic Los Angeles California 90028
Office of Anthony Mills, MD, Inc. Los Angeles California 90069
CARES Sacramento California 95814
University of California Davis Medical Center Sacramento California 95817
San Francisco Veterans Affairs Medical Center San Francisco California 94121
The Kinder Medical Group Miami Florida 33133
Care Resource Miami Florida 33137
Orlando Immunology Center Orlando Florida 32803
Infectious Diseases Associates of Northwest Florida, PA Pensacola Florida 32504
Hillsborough County Health Department Tampa Florida 33602
AIDS Research Consortium of Atlanta Atlanta Georgia 30308
Ruth M. Rothstein CORE Center Chicago Illinois 60612
Nassau University Medical Center East Meadow New York 11554
Greiger Clinic Mount Vernon New York 10550
Rosedale Infectious Diseases Huntersville North Carolina 28078
University of Cincinnati Medical Center Cincinnati Ohio 45267-0405
Saint Hope Foundation - Bellaire Clinic Bellaire Texas 77401
Saint Hope Foundation - Conroe Clinic Conroe Texas 77301
Nicholaos C. Bellos, MD, PA Dallas Texas 75204
University of Texas Southwestern Medical Center at Dallas Dallas Texas 75235
Saint Hope Foundation - Stafford Clinic Stafford Texas 77477

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00823979, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 3, 2018 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00823979 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →